Stage I HR-Positive Invasive Lobular Carcinoma: Erica's Survivor Story

Patient Info: Erica, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative

As of December 2025, Erica had Stage IA ER-positive/PR-positive/HER2-negative ILC removed with negative lymph nodes, completed 16 rounds of radiation, and was focused on survivorship and advocacy.

Lobular Breast Cancer AllianceRead more →

Luminal B-like lobular breast cancer: robotic-assisted nipple-sparing mastectomy with 12-month disease-free follow-up

Patient Info: Anonymized, Female, 40s

Biomarkers: ER 90%; PR 100%; HER2-negative; Ki-67 20%; luminal B-like subtype

As of November 2025, she was disease-free 12 months after neoadjuvant taxane-based chemotherapy and single-port robotic-assisted nipple-sparing mastectomy with immediate reconstruction.

PubMed CentralRead more →

Stage IV ER/PR-positive breast cancer with retinal vein and artery occlusion during endocrine-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER 70%; PR 100%; HER2-negative; Ki-67 10%

Metastatic Site: bone (cranial vault, right first rib, sternum, D5, D6,…

As of November 2025, she continued care for Stage IV ER/PR-positive breast cancer with bone metastases while also managing severe left-eye retinal vascular occlusion and limited visual recovery.

PubMed CentralRead more →

HER2-Positive Breast Cancer: Janella's Survivor Story

Patient Info: Janella Bustamante, Female, 40s

Biomarkers: Triple-positive: estrogen-, progesterone- and HER2-fueled breast cancer

As of October 2025, Janella had completed lumpectomy, chemotherapy, radiation and HER2-targeted biological therapy for triple-positive breast cancer and was on follow-up every 3 months; the source describes life after cancer but does not explicitly state NED/cancer-free.

Cleveland ClinicRead more →

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed CentralRead more →

HER2-positive Stage IV breast cancer: T-DM1 extravasation wound healed after multidisciplinary care

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 70% positive; HER2 IHC 3+

Metastatic Site: pelvis

As of October 2025, the T-DM1 extravasation wound had almost fully healed within about 4 weeks, and the patient continued adjuvant T-DM1 through a port; longer cancer-control status was not described.

PubMed CentralRead more →

Stage II HR-Positive Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Njathi, Female, 40s | Stage II

Biomarkers: Triple-positive; ER-positive; PR-positive; HER2-positive

As of October 2025, Jennifer was more than 1 year past treatment for triple-positive Stage IIA breast cancer and had a recent clear MRI.

City of HopeRead more →

Hormone receptor-positive male breast cancer: spontaneous regression after biopsy and mastectomy

Patient Info: Anonymized, Male, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative; p63 staining confirmed myoepithelial cells in residual benign cystic lesion

Mastectomy and axillary clearance showed no residual invasive carcinoma or carcinoma in situ, with clear margins; he recovered well and began adjuvant tamoxifen because of the original ER/PR-positive biopsy.

PubMed CentralRead more →

Stage 0 ER-positive DCIS: mastectomy without adjuvant therapy, followed by successful pregnancy

Patient Info: Anonymized, Female, 40s | Stage 0

Biomarkers: ER-positive; PgR-positive; HER2-negative; nuclear grade 2; comedo type; negative margins; no lymph node involvement

She completed surgical treatment for Stage 0 DCIS with negative margins and no lymph node involvement, avoided adjuvant therapy, resumed assisted reproductive treatment, and delivered a healthy male infant.

PubMed CentralRead more →

Stage IIA male breast cancer: chemotherapy, mastectomy, endocrine therapy, and benign adrenal nodule

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative

Final breast cancer pathology was T1N1M0 / AJCC Stage IIA ER-positive, PR-positive, HER2-negative invasive ductal carcinoma; the suspicious adrenal lesion was removed in June 2025 and proved to be a benign adrenal adenoma.

PubMed CentralRead more →

Breast cancer survivorship complicated by fatal lymphedema-associated necrotizing soft tissue infection

Patient Info: Anonymized, Female, 50s

Biomarkers: Prior breast cancer: ER-positive, PR-positive, HER2-negative

She died after hospital-acquired pneumonia and acute respiratory failure during recovery from severe right-arm lymphedema-associated necrotizing soft tissue infection after prior breast cancer treatment.

PubMed CentralRead more →

Stage IIIB male encapsulated papillary breast cancer: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: ER-positive 100%; PR-positive 100%; HER2-negative / IHC 1+; p63 loss supported encapsulated papillary carcinoma; no neuroendocrine differentiation

Three years after diagnosis, he was clinically doing well without evidence of breast cancer recurrence after mastectomy, radiation, and tamoxifen.

PubMed CentralRead more →

Stage IIB HER2-positive apocrine breast carcinoma treated with chemotherapy, trastuzumab, radiation, and tamoxifen

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER 80%; PR 5%; HER2-positive by HercepTest and FISH; Ki-67 15%; AR testing not performed

At 7 months of follow-up, the patient remained in remission, with no locoregional recurrence or distant metastasis reported.

PubMed CentralRead more →

Stage 3 breast cancer: complete pathological response to chemotherapy

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

At 1-year follow-up, she remained free of breast cancer; a thyroid nodule found on CT had no malignancy on fine-needle aspiration.

PubMed CentralRead more →

Isolated adrenal metastasis from breast cancer: adrenalectomy and exemestane plus palbociclib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; GATA3-positive; CK7-positive; mammaglobin-positive; GCDFP-15 rare staining

Metastatic Site: right adrenal gland

After laparoscopic right adrenalectomy for isolated metastatic breast carcinoma, follow-up CT abdomen/pelvis and PET-CT showed no metastatic disease elsewhere; surveillance while on exemestane and palbociclib showed no recurrence so far.

PubMed CentralRead more →

ER/PR-positive breast cancer with separate solitary rib plasmacytoma: disease-free after breast and plasmacytoma treatment

Patient Info: Anonymized, Female, 60s

Biomarkers: Breast cancer: ER-positive, PR-positive, HER2-negative

More than 5 years after treatment, she remained disease-free with no recurrence of either ER/PR-positive breast cancer or the separate solitary rib plasmacytoma.

PubMed CentralRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Courtney's Patient Story

Patient Info: Courtney, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

As of June 2025, Courtney was recovering from Stage III ER-positive, PR-positive, HER2-negative ILC treatment after double mastectomy, Taxotere/Cytoxan chemotherapy, and 25 rounds of radiation, with reconstructive surgery delayed by radiation skin injury.

Lobular Breast Cancer AllianceRead more →

Metastatic male breast cancer: complete metabolic response after restarting anastrozole, leuprolide, abemaciclib, zoledronic acid, and radiation

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: ER >95%; PR >95%; HER2/neu-negative; Ki-67 30%; PIK3CA exon 21 pathogenic variant; BRCA1 not mutated; BRCA2 not mutated

Metastatic Site: bone (vertebral bodies T2-T6, L1, and L5)

As of May 2025, after restarting endocrine and targeted therapy and receiving palliative radiation, the last two PET scans showed complete metabolic response without disease progression, and brain MRI showed no metastasis.

PubMed CentralRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Tanya's Patient Story

Patient Info: Tanya, Female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; grade 1

As of May 2025, Tanya was recovering from chest wall surgery, ALT flap repair, and a later skin graft after developing angiosarcoma in her radiated reconstructed breast years after Stage IIIA ILC treatment.

Lobular Breast Cancer AllianceRead more →

Stage IIIB ER/PR-positive breast cancer: emergency mastectomy for infected fungating tumor

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: ER >75%; PR >75%; HER2 0 / HER2-negative; grade 3 invasive ductal carcinoma

As of May 2025, management centered on anastrozole after emergency mastectomy, repeated debridements, wound care, and major postoperative complications; oncology follow-up had become inconsistent because of ongoing medical setbacks.

PubMed CentralRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Rib; spine; pelvis

After a mixed response on the radium trial, Samantha changed to anastrozole and abemaciclib. She described the newer hormone-targeted combination as easier to tolerate and working better while remaining in ongoing treatment.

The Patient StoryRead more →

Stage III HR-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-positive

Three years after diagnosis, Christine described herself in the survivorship stage and focused on the physical and emotional effects that continued after active treatment.

The Patient StoryRead more →

Stage IA ER/PR-positive breast cancer in SLE: arm-behind-back radiation after lumpectomy

Patient Info: Anonymized, Female, 40s | Stage I

Biomarkers: ER >95%; PR >95%; HER2 1+; Ki-67 23%; no BRCA1/2 variants identified

As of April 2025, 15 months after 3D conformal radiotherapy, she had no local recurrence, no distant metastasis, and no radiation pneumonitis.

PubMed CentralRead more →

Stage I HR-Positive Invasive Lobular Carcinoma: Mandy's Patient Story

Patient Info: Mandy, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; low Oncotype score; genetic testing negative for 70 cancer-causing genes

As of April 2025, Mandy was about 10 months after bilateral mastectomy for Stage IA ER-positive, PR-positive ILC, had a low Oncotype score, was planning several years of tamoxifen, and was still in reconstruction.

Lobular Breast Cancer AllianceRead more →